Targeting CaSR/GABAB R1 Heterodimers to Treat Bone Metastases in Breast Cancer

Abstract

The goals of this project were to test whether genetic or pharmacologic inhibition of CaSR/GABAB R1 heterodimers would antagonize the growth and/or survival of breast cancer cells exposed to high extracellular calcium in vitro or grown in animal models of bone metastases in vivo. Over the 3 years plus one no-cost extension, we made progress on achieving all of the tasks outlined in our original SOW. In addition, we initiated new work on how the CaSR and TGF-beta interacted to regulate PTHrP. However, due to a series of technical issues, personnel changes and the ongoing COVID pandemic, we are still working on this project and will carry it forward using discretionary funds in the PIs laboratory. The full details of our efforts are outlined in the attached report.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Dec 01, 2020
Accession Number
AD1152485

Entities

People

  • John J. Wysolmerski

Organizations

  • Yale University

Tags

DTIC Thesaurus Topics

  • Apoptosis
  • Biomedical Research
  • Bone And Bones
  • Bone Diseases
  • Breast Cancer
  • Cancer
  • Cell Line
  • Cell Physiological Processes
  • Cells
  • Diseases And Disorders
  • Hormones
  • Inhibition
  • Medical Personnel
  • Neoplasms
  • Parathyroid Hormones
  • Peptides
  • Production
  • Radiation
  • Students
  • Universities

Fields of Study

  • Biology

Readers

  • Emergency Management and Homeland Security.
  • Oncology (Cancer Research).
  • Technical Research and Report Writing.

Technology Areas

  • Biotechnology